Clinical trials in Breclav

Current clinical trials are focusing on evaluating new therapeutic approaches for active psoriatic arthritis (PsA), particularly in patients with varying treatment histories.

• Biologic-experienced patients
• Biologic-naïve participants
• Anti-TNF resistant cases

These studies aim to assess the effectiveness of novel treatments in reducing PsA symptoms and improving patient outcomes.

Research is centered on investigating innovative compounds including sonelokimab and guselkumab for treating psoriatic arthritis, with special attention to dosing optimization and safety profiles.

• Different dosing regimens
• Safety evaluations
• Efficacy assessments

The studies examine various treatment protocols to determine optimal therapeutic approaches.

Clinical investigations are exploring patient response patterns across different treatment groups, including those who have not responded well to previous therapies.

• Symptom reduction assessment
• Long-term effectiveness
• Treatment comparisons

These trials aim to expand treatment options for patients with varying degrees of disease severity and treatment history.